Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.68 |
| ▸ | PDE5A | O76074 | 1/20 | 0.68 |
| ▸ | PDE9A | O76083 | 1/20 | 0.68 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.68 |
| ▸ | GYS2 | P54840 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.61 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15163884 | 1.00 | PDE4D (0.68) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL29649857 | 0.95 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL29649785 | 0.95 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL24433073 | 0.95 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL12181496 | 0.95 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL24433072 | 0.95 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL12181490 | 0.95 | PDE4D (0.73) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL30925714 | 0.85 | GYS2 (0.85) | PDE4DPDE5APDE9APDE1BGYS2 | |
| SCHEMBL13487370 | 0.85 | PDE4D (0.80) | PDE4DPDE5APDE9APDE1BHSD11B1 | |
| SCHEMBL13487369 | 0.85 | PDE4D (0.80) | PDE4DPDE5APDE9APDE1BHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118657-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-05-03 | — | — | US | disclosed |
| US-9856204-B2 | Methods for inhibiting muscle atrophy | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-01-02 | — | — | US | disclosed |
| US-20140371188-A1 | COMPOSITIONS AND METHODS FOR INHIBITING MUSCLE ATROPHY AND INDUCING MUSCLE HYPERTROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-12-18 | — | — | US | disclosed |
| US-20130203712-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2013-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371188-A1 | COMPOSITIONS AND METHODS FOR INHIBITING MUSCLE ATROPHY AND INDUCING MUSCLE HYPERTROPHY | CDKN1A, MUSK, MSTN | PDE4D 982/4885PDE5A 333/4885PDE9A 1238/4885 |
| US-20180118657-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | TNNC1, PYGM, GYS1 | PDE4D 2142/4885PDE5A 825/4885PDE9A 1876/4885 |
| US-20130203712-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | TNNC1, PYGM, GYS1 | PDE4D 2142/4885PDE5A 825/4885PDE9A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.